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Abstract
Rare mutations in PROC, PROS1 or SERPINC1 as well as common variants in F5, F2, F11
and SERPINC1 have been identified as risk factors for deep vein thrombosis (DVT). To
identify novel genetic risk factors for DVT, we have developed and applied next-generation
DNA sequencing (NGS) of the coding area of hemostatic and proinflammatory genes.
Using this strategy, we previously identified a single nucleotide variant (SNV) rs6050 in the
FGA gene and novel, rare SNVs in the ADAMTS13 gene associated with DVT. To identify
novel coding variants in the genetic predisposition to DVT, we applied NGS analysis of the
coding area of 186 hemostatic and proinflammatory genes in 94 DVT cases and 98 controls
and we identified 18 variants with putative role in DVT. A group of 585 Italian idiopathic DVT
patients and 550 healthy controls was used to genotype all the 18 risk-associated variants
identified by NGS. Replication study in the Italian population identified the rs2232710
variant in the protein Z-dependent protease inhibitor (ZPI) gene to be associated with an
increased risk of DVT (OR 2.74; 95% CI 1.33–5.65; P = 0.0045; Bonferroni P = 0.081). How-
ever, the rs2232710 SNV showed no association with DVT in two Dutch replication cohorts
the LETS study (454 patients and 451 controls) and the MEGA study (3799 patients and
4399 controls), indicating that the rs2232710 variant is not a risk factor for DVT.
Introduction
Deep vein thrombosis (DVT) of the lower extremities has a strong genetic basis, with an esti-
mated hereditary component of 60%, but established genetic risk factors for DVT explain only
a fraction of disease heritability [1,2]. Genetic risk factors include rare mutations in genes
encoding natural anticoagulant proteins such as antithrombin, protein C, protein S or single
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nucleotide polymorphisms (SNPs) in the F5 gene (rs6025 or Factor V Leiden [FVL]) that
impair down-regulation of procoagulant pathway or in the F2 gene (rs1799963 or G20120A)
that result in increased levels of prothrombin [3,4]. Moreover, polymorphisms in several geno-
mic loci such as F11, SERPINC1,HIVEP1, GP6, TSPAN15 and SLC44A2 have recently been
identified in genome-wide association screens (GWAS) as susceptibility loci for DVT [5–8].
The role of the protein Z (PZ) and protein Z-dependent inhibitor (ZPI) pathway in venous
thromboembolism has been recently assessed in clinical studies and using murine models [9].
ZPI is a single-chain glycoprotein that together with its vitamin K-dependent glycoprotein
cofactor PZ inhibits activated coagulation factors X and XI [9]. Several non-synonymous vari-
ants in the ZPI/SERPINA10 gene (henceforth called ZPI), in particular R67X andW303X
mutations, have been identified in patients suffering from thrombophilia [10], even though
other studies did not support these findings [11–13]. Similarly, the association of the PZ-ZPI
pathway with arterial diseases, ischemic stroke, or unexplained early pregnancy loss yielded
conflicting results [14–18]. In animal model, the knockout (KO) of either ZP or ZPI gene
resulted in enhanced thrombotic phenotype following arterial injury [19]. However, the combi-
nation of ZPI deficiency with the homozygous FVL variant led to a more severe thrombotic
phenotype than PZ KO/FVL, implying an important role for the ZPI protein in the inhibition
of activated XI [19]. Recently, two missense mutations F145L and Q384R in the ZPI gene were
shown to impair the inhibitory activity of the ZPI protein in vitro, even though they were not
associated with DVT in humans [20].
The advent of powerful ‘next-generation’ DNA sequencing technology offers unprecedented
opportunities to identify genetic risk factors for complex disorders such as deep vein thrombo-
sis. These novel technologies enable sequencing of large proportions of the human genome (or
even the entire genome) at unparalleled speed and costs. Deep sequencing of all protein-coding
areas of the genome is rapidly becoming the gold standard for the identification of causal genes
underlying the development of both common and rare Mendelian diseases [21–24]. To assess
the potential role of rare coding variants underlying genetic predisposition to venous thrombo-
sis, we have recently developed and successfully applied targeted next-generation DNA
sequencing-based (NGS) strategy and analysis of the coding area of 186 hemostatic and proin-
flammatory genes in Italian idiopathic DVT cases and controls. Using this approach, we identi-
fied a non-synonymous variant rs6050 in the FGA gene [25] as well as several rare coding
single nucleotide variants (SNVs) in the ADAMTS13 gene [26] as risk factors for DVT. The
aim of this study was to assess the potential role of non-synonymous coding variants explain-
ing genetic predisposition to DVT.
Materials and Methods
Participants
The details of the recruitment of DVT patients and healthy controls have been described else-
where [25]. Briefly, DVT patients and healthy controls for this case-control study were from
the DVT-Milan study. A total of 2139 unrelated Italian patients with DVT and 1938 healthy
controls were recruited to the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center
(Milan, Italy) between 1995 and 2010. For this study, we identified 719 unrelated idiopathic
DVT cases that were diagnosed for DVT of the lower limbs. DVT cases were selected according
to the following criteria: (i) objective diagnosis of DVT; (ii) Caucasian ethnicity born from
Caucasian parent; (iii) absence of cancer or surgery associated with DVT; (iv) absence of natu-
ral anticoagulant deficiencies determined by natural levels of protein C, protein S and anti-
thrombin in routine testing; (v) absence of factor V Leiden and prothrombin G20120A
variants determined by sequencing; and (vi) signed informed consent. The study was approved
rs2232710 Variant and Deep Vein Thrombosis
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by the Medical Ethics Committee of the Fondazione IRCCS Ca’ Granda, Hospital Maggiore
and has been carried out in accordance with the code of ethics of the World Medical Associa-
tion (Declaration of Helsinki). Patients recruitment, sampling and thrombophilia screening
was performed at the Angelo Bianchi Bonomi Hemophilia and Thrombosis Center in Milan,
Italy. The next-generation DNA sequencing was performed on 94 idiopathic DVT cases and 98
controls (discovery phase) at the Human Genome Sequencing Center, Baylor College of Medi-
cine, Houston, TX, USA. Replication in the Italian patients and controls as well as in the two
Dutch case-control studies were carried out at the Leiden University Medical Center, Leiden,
Netherlands.
Sequencing and data analysis (discovery phase)
Data presented in this article have been sequenced and analyzed as a part of work previously
described by Lotta et al. [25,26]. The protein-coding regions and intron-exon boundaries of
186 candidate hemostatic and proinflammatory genes were sequenced in 94 Italian cases of idi-
opathic DVT and 98 healthy controls using Applied Biosystems SOLiD 4 sequencing system at
the Human Genome Sequencing Centre (HGSC) at Baylor College of Medicine, Houston,
USA. A gene list is provided elsewhere [25,26]. Variant calling steps included data analysis on
raw reads to produce individual binary alignment/mapping (BAM) files and PILEUP files
using SAMtools [27]. Variants not meeting quality control criteria as specified by the HGSC
were removed. Genetic variants were annotated on the dbSNPvs130 [28], SIFT [29] and Poly-
phen-2 [30] databases using ANNOVAR software [31]. Next, the Nxtgen2plink.rb software
[25] was used to merge individual BAM and PILEUP files that were used for association
analysis.
To carry out association analysis, we estimated the minor allele frequency (MAF) of the var-
iants identified in our discovery cohort of 94 Italian idiopathic DVT cases and 98 matched
healthy controls. Rare variants were defined as MAF 1% and common and low-frequency
variants as those with MAF> 1%. The association of these coding variants with DVT was per-
formed by individual-variant testing using two-sided Fisher’s exact test and by calculating odds
ratio (OR) and 95% confidence interval (CI). In addition, we performed functional annotation
of each variant identifying synonymous, non-synonymous or missense variants predicted to be
damaging by SIFT [29] and Polyphen-2 [30] variant predictor databases. Genetic association
testing was carried out using Plink v1.07 [32] and R programming language [33].
Replication
The Italian replication cohort consisted of 585 idiopathic DVT cases and 550 matched healthy
controls. The top association of the rs2232710 variant with DVT was further tested in two
Dutch studies: in 454 DVT cases and 451 controls of the Leiden Thrombophilia Study (LETS)
[34] and in 3799 cases with a DVT and/or pulmonary embolism and 4399 controls of the Mul-
tiple Environmental and Genetic Assessment of Risk Factors for Venous Thrombosis Study
(MEGA) [35]. Replication was performed using TaqMan genotyping at the Leiden University
Medical Center, Leiden, Netherlands. The obtained results were subjected to chi-squared statis-
tical test. To assess the association of all variants with DVT, OR and 95% CI were calculated.
The P values were two-sided and P<0.05 were considered statistically significant. Bonferroni
correction was used to correct for multiple testing. Genetic association testing was carried out
using Plink [32] and R programming language [33]. Quantile-Quantile (QQ) plots of p-value
distributions for common and low-frequency (MAF> 1%) and rare variants (MAF 1%)
were generated using R programming language [33].
rs2232710 Variant and Deep Vein Thrombosis
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Results
To assess the potential role of coding variants underlying genetic predisposition to DVT, we
applied targeted next-generation DNA sequencing of the coding area of 186 hemostatic and
proinflammatory genes in 94 idiopathic DVT patients and 98 matched healthy controls. As
previously described by Lotta et al. [26], quality control and variant filtering criteria such as
consensus in the presence of mismatches, read-quality and base-quality parameters, allele bal-
ance and strand bias were used to distinguish genetic variants from sequencing errors. In this
way, we identified 4366 SNVs and 187 indels in the 192 individuals that were sequenced with
an average read-depth of 44 over each site. To assess the risk of DVT in individuals carrying
these variants, we calculated minor allele frequencies in cases and controls and performed sin-
gle variant association analysis using two-sided Fisher’s exact test. In this manner, we obtained
a list of 18 genetic variants in 12 genes that showed marked differences in MAF between cases
and controls, and therefore, were selected for further analysis (Table 1).
Among these 18 genetic variants, we identified nine SNVs in genes encoding alpha chains 1,
2 and 3 of Collagen Type IV (COL4A1, COL4A2, COL4A3 genes) and alpha chains 2 and 3 of
Collagen Type VI (COL6A2 and COL6A3). Furthermore, we found two missense variants
rs1176744 and rs17116138 in the 5-Hydroxytryptamine (Serotonin) Receptor 3B (HTR3B)
gene and an intron variant rs5978 and a synonymous variant rs5986 in the Coagulation Factor
XIII, A1 Polypeptide (F13A1) gene. Three genes ZPI,HIF1A and ADRB2 carried missense
substitutions and the TMEM116 and PRKCA genes carried intron and synonymous variants,
respectively (Table 1).
The majority of SNVs identified were common or low-frequency variants with the minor
allele frequencies above 1% (Table 1). In addition, we identified three rare variants, of which
two, the rs2232710 missense variant in the ZPI gene and the rs7133881 intron variant in the
TMEM116 gene were particularly interesting as we did not detect any risk allele in the controls,
indicating that they are probably rare or low-frequency in the general population. The remain-
ing rare variant was the rs36117715 missense substitution in the COL6A3 gene. Furthermore,
we identified 10 variants with the risk allele frequencies higher in patients than in the healthy
individuals, indicating that they could be risk factors for DVT. The remaining SNVs showed
the opposite trend, suggesting a protective role in the development of this disorder (Table 1).
Ten of these 18 variants were non-synonymous missense mutations that resulted in amino
acid substitutions (Table 1). The remaining eight variants were either intronic or synonymous
changes. To assess the putative impact of an amino acid substitution on the structure and func-
tion of the protein, we performed an in silico analysis of all ten missense variants using SIFT
and PolyPhen-2 variant predictor databases. We identified two SNVs, rs2232710 in the ZPI
gene and rs36117715 in the COL6A3 gene that were predicted to be damaging by SIFT predic-
tion (Table 1). The rs2232710 SNV encodes a missense change of Glutamine to Arginine at
position p.Gln384Arg (Q384R) that has been previously shown to impair the inhibitory activity
of the ZPI protein towards activated factor X (FXa) in vitro [20]. The rs36117715 SNV encodes
Proline to Lysine amino acid change at position p.Pro2218Lys (P2218L) and its effect on the
structure or function of the Col6a3 protein is unknown.
Although the advances in NGS technologies have significantly improved sequencing fidel-
ity, the NGS data is still frequently plagued with false-positives and false-negatives [36], which
often leads to signal inflation. For this reason, we generated QQ plots of p-value distributions
of common and low-frequency (MAF> 1%) and rare variants (MAF 1%). As shown in Fig
1, the distribution of p-values of common and low-frequency variants showed good agreement
with the expected distribution, suggesting low bias due to population stratification or technical
artifacts. Rare variants however, showed a deflated p-value distribution. Since a variant can be
rs2232710 Variant and Deep Vein Thrombosis
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Table 1. Single nucleotide variants identified in targeted NGS pilot study in 94 DVT idiopathic patients and 98 healthy controls.
Gene Chr. Genomic
position
dbSNP ID Variant
type
Minor
allele
Protein
change
SIFT Poly-
Phen2
Cases Controls OR
(95%
CI)
P-
value
Alleles MAF Alleles MAF
ZPI/
SERPINA10
14 94750486 rs2232710 missense C Q384R Dam Ben 5 0.03 0 0 NC 0.03
HTR3B 11 113803028 rs1176744 missense C Y129S Ben Ben 47 0.25 67 0.34 0.64
(0.4–1)
0.17
HTR3B 11 113803666 rs17116138 missense A V183I Ben Ben 1 0.01 7 0.04 0.14
(0.02–
1.2)
0.07
HIF1A 14 62207557 rs11549465 missense T P582S Ben Ben 23 0.12 11 0.06 2.3
(1.1–5)
0.05
ADRB2 5 148206440 rs1042713 missense A G16R Ben Ben 70 0.37 53 0.27 1.6
(1.04–
2.5)
0.15
F13A1 6 6196141 rs5978 intron T - - - 37 0.20 20 0.10 2.2
(1.2–
3.8)
0.03
F13A1 6 6174856 rs5986 syn. G E/E - - 30 0.16 14 0.07 2.5
(1.3–
4.8)
0.02
TMEM116 12 112378768 rs7133881 intron C - - - 4 0.02 0 0 NC 0.06
PRKCA 17 64685078 rs2227857 syn. A L/L - - 55 0.29 85 0.43 0.54
(0.4–
0.8)
0.06
COL4A1 13 110839550 rs536174 missense A T555P Ben Ben 17 0.09 32 0.16 0.51
(0.3–
0.95)
0.07
COL4A2 13 111111235 rs7990383 missense A R517K Ben Ben 77 0.41 60 0.30 1.6
(1.03–
2.4)
0.16
COL4A2 13 111119396 rs3803230 missense C G683A Ben Ben 19 0.10 38 0.19 0.47
(0.26–
0.8)
0.03
COL4A2 13 111098226 rs4103 syn. T P/P - - 77 0.41 109 0.55 0.55
(0.4–
0.83)
0.11
COL4A2 13 111109670 rs9515217 intron C - - - 9 0.05 34 0.17 0.24
(0.1–
0.51)
0.001
COL4A3 2 228111435 rs10178458 missense C L141P Ben Ben 32 0.17 52 0.26 0.6
(0.4–
0.93)
0.1
COL6A2 21 47542779 rs17357592 intron T - - - 53 0.28 27 0.14 2.5
(1.5–
4.1)
0.01
COL6A2 21 47541986 rs9976026 intron C - - - 49 0.26 22 0.11 2.8
(1.6–
4.8)
0.002
COL6A3 2 238262021 rs36117715 missense T P2218L Dam Ben 11 0.06 2 0.01 6 (1.3–
28)
0.02
Chr. Chromosome; REF—reference allele sequence; ALT—alternative allele sequence; MAF—minor allele frequency; OR—odds ratio; 95% CI– 95%
conﬁdence interval. SIFT and PolyPhen2 predictions: Syn.–synonymous variant; Dam—damaging, predicted to affect protein function; Ben—benign
(tolerated), predicted to have no effect on protein function; NC—not calculable.
doi:10.1371/journal.pone.0151347.t001
rs2232710 Variant and Deep Vein Thrombosis
PLOS ONE | DOI:10.1371/journal.pone.0151347 March 16, 2016 5 / 11
a true or false positive in context of both inflated and deflated QQ plot, we decided to replicate
all 18 variants identified by targeted sequencing. We applied TaqMan genotyping replication
strategy in 585 Italian idiopathic DVT cases and 550 healthy controls. The number of DVT
cases and healthy controls carrying a given risk allele in respect to an effective sample size
as well as minor allele frequencies in both cases and controls are reported in Table 2. The
only variant associated with DVT in the DVT-Milan replication cohort was the rs2232710 mis-
sense substitution in the ZPI gene with OR = 2.74 (95% CI 1.3–5.7; P = 0.0045; Bonferroni
P = 0.081). We observed the rs2232710-C risk allele in 29 Italian idiopathic DVT cases and 10
healthy controls, corresponding to a MAF of 0.025 and 0.009 for cases and controls, respec-
tively. For the other 17 SNVs, the risk alleles were equally distributed between cases and con-
trols (Table 2), suggesting that these are not susceptibility loci for DVT. The discrepancy
between the MAF obtained from our targeted sequencing and replication of the rs536174 SNV
in the COL4A1 gene is most likely an NGS error. The raw data from our Italian replication
population is presented in S1 Table.
To confirm the association of the rs2232710 missense variant with DVT, we decided to rep-
licate this variant in two independent Dutch studies: in 454 cases and 451 controls in the LETS
study [34] and in 3799 cases and 4399 controls in the MEGA study [35]. Neither of the Dutch
cohorts confirmed our previously obtained association with an OR = 0.71 (95% CI 0.36–1.39)
and OR = 0.92 (95% CI 0.74–1.16) for LETS and MEGA, respectively (Table 3). Indeed, we
observed the rs2232710-C risk allele equally distributed between cases and controls in both
LETs (controls 0.023, cases 0.016) and MEGA (controls 0.019, cases 0.018) (Table 3).
Discussion
In this manuscript, we report the results of targeted next-generation DNA sequencing of the
coding area of 186 hemostatic and proinflammatory genes in 94 idiopathic DVT cases and 98
Fig 1. Quantile-Quantile (QQ) plot of p-value distributions for A. common and low-frequency variants (MAF > 1%) and B. rare variants (MAF 1%).
An arrow indicates the rs2232710 variant.
doi:10.1371/journal.pone.0151347.g001
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Table 2. Association results of the 18 variants identified in the NGS and replicated in up to 585 idiopathic DVT patients and 550 healthy controls
from the DVT-Milan study. Analysis was performed using chi-squared test.
Gene Chr. dbSNP ID Cases Controls Effective sample size OR (95% CI) P-value Bonferroni P-value
Alleles MAF Alleles MAF
ZPI/ SERPINA10 14 rs2232710 29 0.025 10 0.009 1119 2.74 (1.3–5.7) 0.0045 0.081
HTR3B 11 rs1176744 317 0.324 311 0.343 1118 0.9 (0.8–1.1) 0.34 1
HTR3B 11 rs17116138 24 0.021 26 0.024 1119 0.9 (0.5–1.5) 0.58 1
HIF1A 14 rs11549465 143 0.134 132 0.132 1118 1 (0.8–1.3) 0.88 1
ADRB2 5 rs1042713 339 0.374 321 0.365 1113 1 (0.9–1.2) 0.65 1
F13A1 6 rs5978 293 0.301 274 0.300 1117 1 (0.8–1.2) 0.98 1
F13A1 6 rs5986 125 0.116 117 0.116 1118 1 (0.8–1.3) 0.96 1
TMEM116 12 rs7133881 162 0.154 164 0.163 1112 0.9 (0.7–1.2) 0.56 1
PRKCA 17 rs2227857 322 0.338 314 0.352 1116 0.9 (0.8–1.1) 0.48 1
COL4A1 13 rs536174 0 0 1 0.002 1104 NC 0.14 1
COL4A2 13 rs7990383 347 0.389 326 0.373 1118 1.1 (0.9–1.3) 0.44 1
COL4A2 13 rs3803230 153 0.141 156 0.153 1119 0.9 (0.7–1.2) 0.43 1
COL4A2 13 rs4103 453 0.522 416 0.521 1113 1 (0.9–1.2) 0.96 1
COL4A2 13 rs9515217 121 0.108 128 0.122 1118 0.9 (0.7–1.1) 0.3 1
COL4A3 2 rs10178458 208 0.203 206 0.207 1111 1 (0.8–1.2) 0.83 1
COL6A2 21 rs17357592 166 0.154 171 0.169 1044 0.9 (0.7–1.1) 0.21 1
COL6A2 21 rs9976026 159 0.177 171 0.194 1015 0.9 (0.7–1.1) 0.32 1
COL6A3 2 rs36117715 65 0.058 49 0.046 1117 1.3 (0.9–1.9) 0.2 1
Chr. Chromosome; MAF—minor allele frequency; OR—odds ratio; 95% CI– 95% conﬁdence interval; NC—not calculable.
doi:10.1371/journal.pone.0151347.t002
Table 3. Replication analysis of the rs2232710 (SERPINA10/ZPI gene) single nucleotide variant in patients with idiopathic deep vein thrombosis of
lower extremities and heathy controls belonging to three independent cohorts: DVT-Milan, LETS and MEGA. Analysis was performed using chi-
squared test.
rs2232710 genotype
TT TC CC MAF OR (95% CI) P value
DVT-Milan
Controls 529 10 0 0.009 1 (ref)
Cases 551 29 0 0.025 2.74 (1.3–5.7) 0.0045
LETS
Controls 451 19 1 0.023 1 (ref)
Cases 454 13 1 0.016 0.7 (0.4–1.4) 0.32
MEGA
Controls 4399 144 14 0.019 1 (ref)
Cases 3799 127 5 0.018 0.9 (0.7–1.2) 0.48
TOTAL
Controls 5379 173 15 0.018 1 (ref)
Cases 4804 169 6 0.018 1 (0.8–1.2) 0.98
DVT-Milan—Deep Vein Thrombosis Milan Study; LETS—Leiden Thrombophilia Study; MEGA—Multiple Environmental and Genetic Assessment of Risk
Factors for Venous Thrombosis Study; TT—reference genotype; TC—heterozygote for rs2232710-C risk allele; CC—homozygote for rs2232710-C risk
allele; MAF—minor allele frequency; OR—odds ratio; CI—conﬁdence interval.
doi:10.1371/journal.pone.0151347.t003
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matched healthy controls employed to assess the potential role of coding variants underlying
genetic predisposition to DVT. Using this approach we identified 18 single nucleotide variants
in 12 genes with putative role in DVT. Replication of these variants in 585 Italian idiopathic
DVT cases and 550 healthy controls from the DVT-Milan cohort revealed the rs2232710 vari-
ant in the ZPI gene as putative risk factor for DVT. However, independent replication in the
two Dutch studies LETS and MEGA did not reproduce this finding. These results confirmed in
a large replication cohort the lack of association of the rs2232710 variant with DVT that was
previously observed by Young et al. [20].
The reasons for the different prevalence of the rs2232710-C risk allele among controls and
cases in DVT-Milan replication population and in the two independent Dutch cohorts LETS
and MEGA as well as that of Young et al. [20] may be the different recruitment criteria for
patients and controls, different ancestral origin or a random effect due to the relatively small
Italian replication cohort. Since other genetic risk factors such as FVL and prothrombin
G20120A variants or deficiencies in natural anticoagulants (protein C, protein S and anti-
thrombin) can influence the predisposition to develop venous thrombosis, patients carrying
these defects were excluded from our analysis. In the study conducted by Young et al. [20],
only the presence of the FVL variant was reported leaving all the other thrombophilia markers
unchecked. The different patient recruitment criteria may also be a reason for the negative rep-
lication of the rs2232710 in the Dutch population where patients with provoked and unpro-
voked first events of deep vein thrombosis or pulmonary embolism have been included
[34,35].
Another explanation might be the different ancestral origin of the replication cohorts. Our
discovery and first replication cohorts consisted mainly of the Southern European Italian
ancestry, whereas, that of LETS and MEGA were mainly of the Dutch origin and that of Young
et al. [20] of the white British ancestry of New Zealand. Indeed, comparing our study with that
of Young et al. [20] we noticed that with the similar size of the replication cohorts, we observed
marked differences in the prevalence of the rs2232710-C risk allele in DVT patients compared
to controls (5% and 1.9%, respectively), while the previous study did not. We also found differ-
ences in MAF in controls coming from our DVT-Milan study and those from LETS and
MEGA studies. In comparison to the frequency of the rs2232710-C risk allele in controls from
the DVT-Milan, we observed a 2.5-fold and 2.1-fold increase in MAF of controls from LETS
and MEGA, respectively. Moreover, we found the rs2232710-C risk allele present in homozy-
gous state (rs2232710-C/C) in both cases and controls in the LETS and MEGA studies but
none in our DVT-Milan study (Table 3). To verify this result, we analyzed the prevalence of
the rs2232710-C risk allele in healthy European individuals in the 1000 Genomes project phase
3 [37] and the HapMap project phase 3 [38]. We found that in the 1000 Genomes project, the
MAF for Italian (Population of Tuscany; TSI) and Iberian populations were identical (0.9%) to
that obtained from our replication in the heathy Italian individuals. In comparison, the allele
frequency found in the British population from England and Scotland was 1.6%. Similar esti-
mates were obtained when looking at the HapMap project with the MAF of 1.1% and 1.8% for
the Italian Tuscany population and general European population, respectively. Since the results
of both the 1000 Genomes and the HapMap projects were based on relatively small number of
alleles sequenced, we decided to check the estimates for the rs2232710-C risk allele in the
Exome Variant Server (URL: http://evs.gs.washington.edu/EVS/; accessed on 18 September
2015) and we found the minor allele frequency for our variant to be 1.1% (with sequences from
8502 alleles from 4251 European Americans). Based on these observations, especially when
considering that the healthy Italian and the Iberian individuals harbor similar allele frequen-
cies, one is tempted to speculate about a potential prothrombotic role of the rs2232710-C risk
allele solely in the Southern European populations. However, a large-scale genotyping studies
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in the Southern European ancestries would have to be conducted to confirm the rs2232710 var-
iant as a risk factor for DVT in the Southern European populations.
Similar, however opposite effects have been observed for a nonsense mutation, Trp303Stop
(W303X), in the ZPI gene. The W303X has been identified as risk factor for DVT in the New
Zealand white British ancestry [10]. In the Southern European Spanish and Italian ancestries
however, the presence of the W303X mutation is rare and is not associated with DVT [11–13],
suggesting that it may have a thrombotic relevance only in the Northern European ancestries.
However, sampling error due to the limited replication cohorts may have influenced the results
obtained for the rs2232710 SNV in our Italian population as well as those obtained by Van der
Water et al. [10] for the W303X mutation. In fact, correcting the results of our Italian replica-
tion analysis for multiple testing using the Bonferroni correction revealed borderline signifi-
cance for the rs2232710 variant (Table 2). In addition, QQ plot analysis of the p-value
distribution of rare variants showed a greatly deflated signal (Fig 1). Although this kind of
behavior is frequently observed in p-value distributions of rare variants where large P values
are obtained due to the rarity of their allele counts, it may also reflect bias based on population
stratification, differences between cases and controls, lack of statistical power or sequencing
errors.
In conclusion, our NGS analysis revealed 18 variants with putative role in DVT. One of
them, a missense variant rs2232710 (Q384R) in the ZPI gene, was associated with DVT in the
Southern European, Italian replication cohort. An independent, large-scale replication in two
Dutch cohorts did not confirm this association, implying that the presence of this variant does
not increase the risk for venous thrombosis.
Supporting Information
S1 Table. The raw data from our Italian replication population.
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